CHF 02252: Investigating a Ketogenic Medium-Chain Triglyceride (MCT) Supplement for the Treatment of Drug-Resistant Canine Idiopathic Epilepsy and Its Behavioral Comorbidities
Holger Andreas Volk, DVM, PhD; Royal Veterinary College, University of London
Learn more HERE.
CHF 02323: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy
Stephanie McGrath, DVM, MS; Colorado State University
Learn more HERE.
CHF 02489: Tumor-permissive Collagen Signatures in Canine Mammary Gland Tumors: Development of Prognostic Markers and Targeted Therapies for Improved Outcomes
Susan W. Volk, VMD, PhD; University of Pennsylvania
Learn more HERE.
CHF 02534: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma
Erin B. Dickerson, PhD and Antonella Borgatti, DVM, MS; University of Minnesota
Learn more HERE.
CHF 02561: Is Gut Dysbiosis Associated with Canine Idiopathic Epilepsy?
Karen R. Muñana, DVM, MS; North Carolina State University
Learn more HERE.
CHF 02610-A: The Role of Motilin Signaling in Canine Osteoarthritis
Li Zeng, PhD; Tufts University
Learn more HERE.
CHF 02643-A: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity
Joseph J. Wakshlag, DVM, PhD; Cornell University
Learn more HERE.
